The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District court for the Eastern District of New York on behalf of investors who purchased Rockwell Medical, Inc. (NASDAQ: RMTI) securities between November 8, 2017 and June 26, 2018.
According to the RMTI lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Rockwell was aware that The Centers for Medicare and Medicaid Services will not pursue Rockwell’s proposal for separate reimbursement for the drug Triferic; (2) the estimated reserves in the first quarter 2018 10-Q are misstated; (3) there was a material weakness in Rockwell’s internal controls over financial reporting; (4) consequently, Rockwell’s internal controls over financial reporting were ineffective during the Class Period; (5) Defendant Chioini withheld material information regarding Triferic from Rockwell’s auditor, corporate counsel and five independent directors of the Board; and (6) as a result, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked reasonable bases at all relevant times.
"Rockwell Medical, Inc."
If you suffered a loss in Rockwell Medical, Inc. you have until September 25, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
To receive more information, please fill out the form.